Pricing Log in Create free account
Friday 6 November 2026 Export IRTC’s income statement to Excel — free account

iRhythm Holdings, Inc.

IRTC Healthcare Medical Devices

iRhythm Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $747.1 million, up 26.2% from fiscal 2024.

Revenue
+14.9%
EPS
−462.5%
Free cash flow
−157.6%
Total debt
+0.48%

Quarter to September 2026, against a year earlier

89.89 40.30 −30.95%
Market cap
$4.3B
P/E
0.0×
Fwd P/E
−311×
Dividend yield
—
F-score
5/9
Altman Z
4.02
Beneish M
−3.04
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.06
Sold, $m 23.86
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — 1 — — — — — —
Sell 2 — 11 9 — 1 2 2 8 1 — —
Insider Ownership 2.50%

Capital & Financial Ratios $m

Size
Market Cap 4,290.00
Revenue ttm 854.04
Net income ttm (38.59)
Free cash flow ttm 7.38
Net debt Q 91.14
Valuation
P/E 0.00
Forward P/E (311.00) (negative: loss-making)
Price / sales 5.05
Forward P/S Powerpack
Price / FCF 584.40
Price / book 24.36 (above 6: high)
Financial health
Current ratio Q 3.57 (at or above 1.5: strong)
Debt / equity Q 3.68 (above 2: weak)
Interest coverage Q (9.87)
Growth
Revenue growth Q +14.88% (above 0%: growing)
Operating income growth Q −286.23% (below 0%: shrinking)
EPS, this year +76.61% (at or above 15%: strong)
EPS, next year A +455.42% (at or above 15%: strong)
Revenue, next year A +19.35% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +40.27% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 5.2×, against a ten-year median of 8.6×; over the ten years it ranged from 1.1× in 2016 to 26.8× in 2020.
P/S against its own 10 years 16.55%
10-year low 10-year high
P/B against its own 10 years 63.56%
10-year low 10-year high
EV/Sales against its own 10 years 17.54%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 134 536 584 561
Receivables 61 80 76 81
Inventory 14 14 22 23
Other — — — —
231 646 703 730
2023 2024 2025 Q'26
Payables 6 7 2 15
ST’ Debt — — — —
Other — — — —
107 111 152 205

Compound Annual Growth %

10y 5y 3y
Sales 35.38% 23.02% 22.05%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% (14.87%) (13.96%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.01 Actual 0.58

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.36 −0.06 Beat by 0.30
Q4 FY25 0.02 0.29 Beat by 0.27
Q1 FY26 −0.56 −0.35 Beat by 0.21
Q2 FY26 −0.01 0.58 Beat by 0.59
Q3 FY26 0.02 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.43) (0.01) (0.90) — —
’25 (0.97) (0.44) (0.16) 0.17 (1.39)
’24 (1.47) (0.65) (1.48) (0.04) (3.63)
’23 (1.29) (0.61) (0.89) (1.26) (4.04)
’22 (1.71) (0.80) (0.71) (0.67) (3.88)
’21 (0.95) (0.59) (0.81) (1.10) (3.46)
’20 (0.34) (0.75) (0.17) (0.33) (1.58)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 199 224 222 — —
’25 159 187 193 209 747
’24 132 148 148 164 592
’23 111 124 125 133 493
’22 92 102 104 113 411
’21 74 81 85 82 323
’20 64 51 72 79 265
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (26) 51 4 — —
’25 (8) 28 35 26 81
’24 (52) 12 24 19 3
’23 (31) (5) 1 (16) (50)
’22 (39) 0 4 13 (23)
’21 (42) (1) 18 (13) (38)
’20 (22) (10) 11 8 (14)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (33) 38 (12) — —
’25 (17) 17 20 14 35
’24 (62) 3 1 12 (46)
’23 (39) (14) (8) (29) (91)
’22 (44) (11) (3) 5 (53)
’21 (46) (6) 4 (18) (66)
’20 (26) (12) 5 5 (27)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 64 99 147 215 265 323 411 493 592 747 854 +31.4% 892 1,040 1,197 +17.0%
Gross margin, % 67.41 71.55 73.66 75.54 73.50 66.16 68.54 67.35 68.86 70.57 72.26 +3.2 pt
EBT (21) (30) (50) (55) (44) (101) (116) (123) (113) (44) (38) +8.5%
EBT margin, % (32.62) (30.00) (34.18) (25.40) (16.44) (31.28) (28.20) (24.90) (19.05) (5.84) (4.41) +26.8 pt
Net income (21) (30) (50) (55) (44) (101) (116) (123) (113) (45) (39) +8.8%
Per share, $
Per share, $ Revenue 12.12 4.38 6.17 8.49 9.55 11.01 13.74 16.14 18.97 23.35 25.80 +7.6%
Earnings (3.95) (1.30) (2.02) (2.16) (1.58) (3.46) (3.88) (4.04) (3.63) (1.39) (1.17) (11.0%)
Cash flow (3.15) (0.66) (1.22) (0.87) (0.50) (1.29) (0.77) (1.64) 0.11 2.53 1.68 n/m
Capex (0.52) (0.16) (0.22) (0.81) (0.49) (0.96) (1.00) (1.32) (1.57) (1.45) (1.46) +12.0%
Free cash flow (3.67) (0.82) (1.43) (1.67) (0.98) (2.24) (1.77) (2.97) (1.46) 1.08 0.22 n/m
Book value 17.51 3.52 2.18 5.36 12.31 9.53 8.02 6.88 2.91 4.77 5.35 (13.4%)
Shares, m 5 23 24 25 28 29 30 31 31 32 33 +22.2%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 2.47 13.14 11.27 8.02 24.83 10.69 6.85 6.28 4.75 7.60 5.05 9.6
P/B 1.71 16.38 31.83 12.70 19.27 12.35 11.74 14.73 30.94 37.18 24.36 18.9
EV/Sales 1.32 12.45 10.98 7.53 23.69 10.02 6.44 6.10 4.96 7.70 5.17 9.1
EV/FCF (4.36) (66.83) (47.20) (38.16) (230.00) (49.14) (50.11) (33.21) (96.08) 166.74 598.33 (44.8)
Cash, $m
Cash, $m Operating cash flow (17) (15) (29) (22) (14) (38) (23) (50) 3 81 56 n/m
Capex (3) (4) (5) (20) (14) (28) (30) (40) (49) (46) (48) +36.8%
Free cash flow (19) (18) (34) (42) (27) (66) (53) (91) (46) 35 7 n/m
Balance, $m
Balance, $m Working capital 105 99 74 121 312 218 200 123 535 551 525 +20.2%
Net debt (74) (68) (43) (106) (302) (218) (178) (99) 111 66 91 n/m
Shareholders’ equity 93 80 52 135 342 280 240 210 91 153 177 +5.7%
Returns, %
Returns, % ROA (23.75) (21.93) (40.20) (25.76) (10.72) (20.80) (25.50) (28.00) (16.60) (4.57) (3.70) +19.2 pt
ROIC (52.22) (154.41) (328.50) (114.87) (69.28) (101.17) (115.44) (70.29) (35.77) (16.42) (11.42) +35.8 pt
ROE 461.33 (34.56) (76.51) (58.19) (18.38) (32.64) (44.73) (54.86) (75.27) (36.57) (25.81) (497.9) pt
People
People Employees 406 575 748 997 1,157 1,700 1,793 2,000 2,000 2,400 — +21.8%
Revenue/emp, $m 0.16 0.17 0.20 0.22 0.23 0.19 0.23 0.25 0.30 0.31 — +7.8%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

iRhythm Holdings, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TXG 10x Genomics $7.6B — (loss-making) — (loss-making) −12.65% (below 0%: shrinking) n/m −4.61% (below 0%: shrinking) 74.48% (12.95%) Compare
HAE Haemonetics Corporation $5.7B 54.5× 30.2× +9.30% (above 0%: growing) +25.93% (above 0%: growing) +20.37% (above 0%: growing) 61.75% 21.00% Compare
LIVN LivaNova PLC $5.0B 25.6× 19.8× +9.88% (above 0%: growing) +27.41% (above 0%: growing) −30.95% (below 0%: shrinking) 67.41% 7.22% Compare
ITGR Integer Holdings Corporation $4.3B 42.2× 38.9× −3.86% (below 0%: shrinking) −61.04% (below 0%: shrinking) −65.19% (below 0%: shrinking) 22.59% 6.27% Compare
IRTC iRhythm Holdings, Inc. $4.3B — (loss-making) — (loss-making) +14.88% (above 0%: growing) n/m −157.58% (below 0%: shrinking) 74.23% (14.69%)
AXGN AxoGen, Inc. $2.9B — (loss-making) — (loss-making) +26.22% (above 0%: growing) +163.16% (above 0%: growing) +994.99% (above 0%: growing) 74.81% 1.26% Compare
NEOG Neogen Corporation $2.6B — (loss-making) — (loss-making) +6.50% (above 0%: growing) n/m +135.61% (above 0%: growing) 47.35% (0.81%) Compare
TMDX TransMedics Group, Inc. $2.4B 16.4× 49.4× +41.15% (above 0%: growing) −30.99% (below 0%: shrinking) −55.44% (below 0%: shrinking) 58.45% 13.86% Compare
UFPT UFP Technologies, Inc. $2.3B 30.1× 29.2× +11.57% (above 0%: growing) +25.55% (above 0%: growing) −35.77% (below 0%: shrinking) 29.44% 16.01% Compare
Median of peers $3.6B 30.1× 30.2× +9.59% +25.74% −17.78% 60.10% 6.75%

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 17 April 2026

Ownership

Directors and executive officers, together 0.98%
BlackRock, Inc.5 8.57%
Sands Capital Management, LLC6 5.17%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

iRhythm Holdings, Inc. (IRTC) Latest News

6 Nov

Impact 4 · · The Motley Fool transcript
Impact 3 · · MarketBeat

5 Nov

Impact 4 · · GlobeNewswire
Impact 3 · · StockStory

29 Oct

Impact 3 · · Zacks

28 Oct

Impact 4 · · Simply Wall St.

27 Oct

Impact 3 · · StockStory

18 Oct

Impact 3 · · Simply Wall St.

17 Oct

Impact 4 · · Simply Wall St.
Impact 3 · · Simply Wall St.

9 Oct

Impact 3 · · Simply Wall St.

5 Oct

Impact 4 · · GlobeNewswire

22 Sep

Impact 4 · · Zacks

21 Sep

Impact 3 ·

4 Sep

Impact 3 ·

15 Aug

Impact 3 ·

14 Aug

Impact 4 ·

13 Aug

Impact 4 · · The Motley Fool transcript

12 Aug

Impact 3 ·

10 Aug

Impact 4 ·
Impact 4 ·
Impact 4 · · medtechdive.com

9 Aug

Impact 4 ·

8 Aug

Impact 4 ·

7 Aug

Impact 4 ·
Impact 4 · · medicaldevice-network.com
Impact 4 · · Moby transcript
Impact 4 · transcript

6 Aug

Impact 3 · · MarketBeat transcript
Impact 3 ·

IRTC metrics, ten years each

stockrow.com/IRTC · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com